ZURICH (Reuters) - The European Medicines Agency (EMA) has accepted an application to review Sandoz’s biosimilar to Amgen’s EU-licensed Neulasta (pegfilgrastim), a recombinant human granulocyte colony-stimulating factor, Sandoz parent Novartis said on Thursday.
Sandoz is seeking approval for the same indication as the reference product, it added in a statement.
The U.S. Food and Drug Administration in November accepted Sandoz’s submission for approval of a biosimilar version of Amgen’s Neulasta drug that fights infections in cancer patients.
Reporting by Michael Shields
Our Standards: The Thomson Reuters Trust Principles.